412 related articles for article (PubMed ID: 22133052)
1. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
3. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
4. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S
Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503
[TBL] [Abstract][Full Text] [Related]
5. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.
Gardette A; Ottaviani S; Tubach F; Roy C; Nicaise-Roland P; Palazzo E; Gill G; Meyer O; Dieudé P
Joint Bone Spine; 2014 Oct; 81(5):416-20. PubMed ID: 24998790
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
9. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry.
Couderc M; Gottenberg JE; Mariette X; Pereira B; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Soubrier M;
Rheumatology (Oxford); 2014 Oct; 53(10):1788-93. PubMed ID: 24821852
[TBL] [Abstract][Full Text] [Related]
10. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
[TBL] [Abstract][Full Text] [Related]
11. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
13. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
[TBL] [Abstract][Full Text] [Related]
14. Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs.
Iannone F; Tampoia M; Giannini M; Lopalco G; Cantarini L; Villalta CD; Galeazzi M; Lapadula G
Clin Exp Rheumatol; 2016; 34(3):424-9. PubMed ID: 26885600
[TBL] [Abstract][Full Text] [Related]
15. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
Keystone EC; Cohen SB; Emery P; Kremer JM; Dougados M; Loveless JE; Chung C; Wong P; Lehane PB; Tyrrell H
J Rheumatol; 2012 Dec; 39(12):2238-46. PubMed ID: 23027887
[TBL] [Abstract][Full Text] [Related]
16. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
[TBL] [Abstract][Full Text] [Related]
17. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Belmonte Serrano MA; Pincus T
Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
[No Abstract] [Full Text] [Related]
18. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.
Solau-Gervais E; Prudhomme C; Philippe P; Duhamel A; Dupont-Créteur C; Legrand JL; Houvenagel E; Flipo RM
Joint Bone Spine; 2012 May; 79(3):281-4. PubMed ID: 21724444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
